The Q3 results topped expectations, with strong growth witnessed across the targeted therapeutic areas. Consequently, the management upgraded its 2023 guidance for the third time this year. The ytd gain in the Novartis share price (amongst the top performing AV Big Pharmas) could see further support in the event that the company continues to utilise its balance sheet strength to pursue inorganic opportunities, especially considering the cardiovascular drug Entresto’s upcoming patent expiries. Ov ....
